Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.54 |
| ▸ | GRIK1 | P39086 | 14/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.48 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5468406 | 0.86 | KCNMA1 (0.56) | KCNMA1MEN1KMT2APKMALDH1A1 | |
| SCHEMBL5460243 | 0.86 | KCNMA1 (0.50) | KCNMA1MEN1KMT2APKMNPSR1 | |
| SCHEMBL5460406 | 0.81 | KCNMA1 (0.62) | KCNMA1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL14363391 | 0.77 | PPARG (0.66) | KCNMA1GRIK1MEN1KMT2APKM | |
| SCHEMBL1308769 | 0.77 | PPARG (0.69) | GRIK1MEN1KMT2APKMNPSR1 | |
| SCHEMBL1308714 | 0.74 | MEN1 (0.76) | KCNMA1GRIK1MEN1KMT2APKM | |
| SCHEMBL5462668 | 0.74 | TAS1R3 (0.52) | KCNMA1MEN1KMT2APKMKDM4E | |
| SCHEMBL1308314 | 0.73 | GRIK1 (0.69) | KCNMA1GRIK1MEN1KMT2APKM | |
| SCHEMBL29183052 | 0.73 | GRIK1 (0.68) | GRIK1MEN1KMT2APKMNPSR1 | |
| SCHEMBL1310106 | 0.73 | GRIK1 (0.74) | KCNMA1GRIK1MEN1KMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1666469-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | KCNMA1 1503/4885GRIK1 1755/4885MEN1 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.